Becton Dickinson & Co stock faces analyst scrutiny as Argus cuts price target to $180 amid medtech s

2026-03-26 16:26:20

Argus Research has lowered its price target for Becton Dickinson & Co (NYSE:BDX) to $180 from a prior higher level, while maintaining a Buy rating. This adjustment reflects ongoing challenges in the medtech sector, including margin pressures, rising input costs, and slower procedural volumes. Despite the lowered target, the firm retains a ‘Buy’ rating, signaling long-term potential, with the stock exhibiting defensive qualities and offering a dividend yield.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.